News

The combination of pembrolizumab and lenvatinib appears to be effective in for the treatment of patients with endometrial cancer, regardless of biomarker status.

Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.

In an interview with Targeted Oncology, Randeep Sangha, MD, discussed the background of the phase 1 study and the rationale for studying zelenirstat for the treatment of solid tumors and hematologic malignancies.

The combination of olaparib and abiraterone acetate resulted in a postponement of disease progression and enhanced outcomes for individuals with mutations in BRCA, ATM, and CDK12 in metastatic castration-resistant prostate cancer.

A post hoc sensitivity analysis that counted use of subsequent therapies in patients censored from primary overall survival follow-up favored darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Regarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.

A higher dose of radiation therapy led to longer progression-free, cancer-specific, and overall survival, compared with the standard dose, in combination with long-term ADT in patients with high-risk prostate cancer.

Benjamin H. Lowentritt, MD, FACS, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide.

Research suggests that combining cabozantinib with atezolizumab could emerge as a promising alternative for individuals facing metastatic castration-resistant prostate cancer that has advanced after novel hormonal therapy.

Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.

A promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.

Prior treatment with external beam radiation therapy did not increase incidence of hematological toxicity relative to the overall population of patients with metastatic castration-resistant prostate cancer treated with radium-223.

While germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.

Findings from 2 Chinese clinical trials of olverembatinib support its addition to The National Comprehensive Cancer Network guidelines for the treatment of patients with chronic myeloid leukemia.

Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.

Thomas Powles, MD, MBBS, MRCP, discusses the mechanism of action of enfortumab vedotin-ejfv and its use in treating locally advanced or metastatic urothelial carcinoma.

In the first article of a 2-part series, Yara Abdou, MD, discussed the most significant challenges and transformative advancements in the treatment of HER2-positive breast cancer.

Matthew A. Powell, MD, discusses the methods and design of the randomized, double-blind, phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial in endometrial cancer.

In an interview with Targeted Oncology, Charu Aggarwal, MD, MPH, discussed the real-world study evaluating the link between molecular genotyping and survival among patients with non–small-cell lung cancer.

In an interview for Cervical Cancer Awareness Month, Robert P. Edwards, MD, discussed the current treatment landscape of cervical cancer as well as future prospects.

The FDA has approved the investigational new drug application for HBM9027, a bispecific antibody.

The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.

An investigational new drug for BSI-082 has been cleared by the FDA for the treatment of hematologic and solid tumors.

Tamoxifen, a selective estrogen receptor modulator, shows potential as a line of treatment in some patients with myeloproliferative neoplasms.

Federico Albrecht, MD, discusses the standard practice on testing for a patient with small cell lung cancer at Miami Cancer Institute.

Patients with extensive-stage small cell lung cancer experienced longer rates of survival when treated with atezolizumab induction and maintenance therapy vs placebo.

In an interview with Targeted Oncology, Jie Jin, MD, discussed the need for a standard therapy in peripheral T-cell lymphoma and highlighted the potential impact of the JACKPOT26 study.

The FDA has accepted the biologics license application for obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

In an interview with Targeted Oncology, Guenther Koehne, MD, provides a comprehensive overview of the dynamic landscape and evolving strategies in immunotherapy for hematologic malignancies.

Neeraj Agarwal, MD, highlights several exciting prostate cancer developments being presented at the upcoming 2024 Genitourinary Cancers Symposium.